Abstract
Man is unable to actively eliminate iron from the body, once it has been acquired. Toxic and eventually lethal levels of iron accumulate as a result of repeated transfusions, e.g. in ß-thalassemia major, or due to excessive dietary iron uptake in anemias and hereditary hemochromatosis. Excess iron is deposited in the form of hemosiderins (insoluble “iron cores” of ferritin) mainly in the liver, spleen, many endocrine organs and in the myocardium. The exact mechanism of iron damage to these tissues is unknown, but it is established that organ failure correlates with iron burden in these tissues. Except for infectious diseases, cardiac complications are the major cause of death in ß-thalassemia major patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E., Harris, J.W. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major.New Engl. J. Med.1994,331, 567–573.
Gabutti, V., Piga, A. Results of Long-term Iron Chelating Therapy.Acta Haematol.19969526–36.
Olivieri, N.F.; Nathan, D.G.; MacMillan, J.H.; Wayne, A.S.; Liu, P.P.; McGee, A.; Martin, M.; Koren, G.; Koren, A.R. Survival in Medically Treated Patients with Homozygous ß-Thalassemia.New Engl. J. Med.1994,331, 574–578.
Hams, W.R., Raymond, K.N., Weitl. F.L. Ferric Ion Sequestring Agents: The Spectrophotometric and Potentiometric Evaluation of Sulfonated Tricatecholate Ligands.J. Am. Chem. Soc.19811032667–2675.
Bergeron, R.J., Wiegand, J., Dionis, J.B., Egli-Karmakka, M., Frei, J., Huxley-Tencer, A., Peter, H.H. Evaluation of Desferrithiocin and its Synthetic Aanalogues as Orally Effective Iron Chelators.J. Med. Chem.1991342072–2078.
Pippard, M.J., Groves, M.J., Hider, R.C. Effects of Hydroxypyridinone Chelating Agents on Internal Iron Exchange.Br. J. Haematol.1991,77 (Suppl1), 39.
Finch, C.A., Ragan, H.A., Dyer, I.A., Cook, J.D. Body Iron Loss in Animals.Proc. Soc. Exp. Biol. Med.1978159335–338.
Bergeron, R.J., Streiff, R.R., Creary, E.A., Daniels, R.D. Jr., King, W., Luchetta, G., Wiegand, J., Moerker, T., Peter, H.H. A Comparative Study of the Iron-clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model.Blood1993, 15, 81(8): 2166–2173.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic/Plenum Publishers, New York
About this chapter
Cite this chapter
Nick, H. et al. (2002). ICL670A: Preclinical Profile. In: Hershko, C. (eds) Iron Chelation Therapy. Advances in Experimental Medicine and Biology, vol 509. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0593-8_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0593-8_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46785-1
Online ISBN: 978-1-4615-0593-8
eBook Packages: Springer Book Archive